\begin{tabular}{p{6cm}cc}
& \multicolumn{2}{c}{\textbf{England Prevalence (\%)  }} \\[0.5ex] &
  \emph{OpenSafely Sample} & \emph{This Study} \\[2ex]
Age 18-39 & \num{34.4} & \num{$$uk_age_18_40$$} \\[0.25ex]
Age 40-49 & \num{16.5} & \num{$$uk_age_40_50$$} \\[0.25ex]
Age 50-59 & \num{17.6} & \num{$$uk_age_50_60$$}\\[0.25ex]
Age 60-69 & \num{13.8} & \num{$$uk_age_60_70$$}\\[0.25ex]
Age 70-79 & \num{11.2} & \num{$$uk_age_70_80$$}\\[0.25ex]
Age 80-99 & \num{6.5} & \num{$$uk_age_80$$} \\[0.25ex]
Male & \num{49.9} & \num{$$male$$} \\[0.25ex]
Diabetes (Controlled) & \num{6.0} & \num{$$uk_prev_diabetes_contr$$} \\[0.25ex]
Diabetes (Uncontrolled) & \num{2.8} & \num{$$uk_prev_diabetes_uncontr$$} \\[0.25ex]
Hypertension & 34.2} & \num{$$uk_prev_hypertension_both$$} \\[0.25ex]
Obese (class I \& II) & \num{19.1} & \num{$$uk_prev_obese_1_2$$} \\[0.25ex]
Obese (class III) & \num{2.7} & \num{$$uk_prev_obese_3$$} \\[0.25ex]
Chronic Heart Disease & \num{6.7} & \num{$$uk_gbd_chronic_heart_dz_mu$$} \\[0.25ex]
Chronic Respiratory Disease & \num{4.1} & \num{$$uk_prev_chronic_resp_dz$$}
\\[0.25ex]
Asthma & \num{1.7} & \num{$$uk_gbd_asthma_ocs_mu$$} \\[0.25ex]
Kidney Disease & \num{6.3} & \num{$$uk_gbd_kidney_dz_mu$$} \\[0.25ex]
Chronic Liver Disease & \num{0.7} & \num{$$uk_gbd_liver_dz_mu$$} \\[0.25ex]
Haematological Cancer & \num{0.1} & \num{$$uk_gbd_haem_malig_1_mu$$}\\[0.25ex]
Non-haematological Cancer & \num{0.5} & \num{$$uk_gbd_cancer_non_haem_1_mu$$} \\[0.25ex]
Stroke, Dementia & \num{2.1} & \num{$$uk_gbd_stroke_dementia_mu$$} \\[0.25ex]
Other Neurological Condition & \num{1.0} & \num{$$uk_gbd_neuro_other_mu$$} \\[0.25ex]
Psoriasis, Rheumatoid & \num{5.1} & \num{$$uk_gbd_autoimmune_dz_mu$$} \\[0.25ex]
Other Immunosuppressive Conditions & \num{1.6} & \num{$$uk_gbd_immuno_other_dz_mu$$} \\[0.25ex]
\end{tabular}
